Topic: Merkel cell carcinoma
The week’s biotech news included a potential boost to cancer immunotherapy and new insight into a dementia-causing protein.
For many years, Pfizer was hit by waves of criticism for its failure to develop new blockbusters to replace the big drugs that had bulked up its revenue. Those critics wanted to see more outsourcing, more partnerships and smaller in-house research empires. Pfizer has in many ways steered toward that course, and 2016 saw more evidence of this.
Pfizer and Merck KGaA took a step closer to becoming the fourth to market in the new checkpoint inhibitor space as they announce that the FDA has accepted for review their BLA for avelumab as they eye a possible 2017 approval.